Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.

ABSTRACT:

Importance

Selecting effective antidepressants for the treatment of major depressive disorder (MDD) is an imprecise practice, with remission rates of about 30% at the initial treatment.

Objective

To determine whether pharmacogenomic testing affects antidepressant medication selection and whether such testing leads to better clinical outcomes.

Design, setting, and participants

A pragmatic, randomized clinical trial that compared treatment guided by pharmacogenomic testing vs usual care. Participants included 676 clinicians and 1944 patients. Participants were enrolled from 22 Department of Veterans Affairs medical centers from July 2017 through February 2021, with follow-up ending November 2021. Eligible patients were those with MDD who were initiating or switching tre

SUBMITTER: Oslin DW 

PROVIDER: S-EPMC9277497 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature